C4 Therapeutics, Inc. (CCCC) AI Stock Analysis
CCCC AI stock analysis summary
AI ResearchC4 Therapeutics, Inc. (CCCC) is a clinical-stage biopharmaceutical company developing targeted protein degraders for cancer and other conditions. In FY2025, the company generated $35.9M in revenue while reporting net income of -$105.0M and free cash flow of -$99.3M. As of June 30, 2026, it held $253.7M in cash and short-term investments, supporting ongoing clinical trials.
- Market cap
- $340.2M
- Revenue (TTM)
- $35.0M
- P/E
- —
- 1Y return
- 11.5% S&P 500 16.8%
- Avg. target
- $12.86 365.0% vs last close
Bull case
- All 8 covering analysts rate the stock a Buy or Strong Buy, with a mean price target of $12.86 representing 365.0% upside from the last close of $2.77.
- The company maintains a solid liquidity reserve with $253.7M in cash and short-term investments and net cash of $196.8M as of June 30, 2026.
- C4 Therapeutics has beaten earnings per share estimates in each of the last 4 quarters, while FY2026 EPS is projected to improve 24.7%.
Bear case
- The company continues to incur operating deficits, reporting free cash flow of -$99.3M and an operating margin of -290.7% in FY2025.
- Analyst consensus anticipates revenue to decline 15.6% next fiscal year to $22.3M, down from the $26.4M estimated for FY2026.
- Shareholder dilution has been substantial, with the company's share count increasing 169.5% over the past 5 years.
What C4 Therapeutics does
C4 Therapeutics, Inc., based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical firm developing novel therapeutic candidates to degrade disease-causing proteins for cancer and neurodegenerative diseases. Its lead candidate, CFT7455, is an orally bioavailable MonoDAC degrader in Phase 1/2 trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas. The company's pipeline also includes CFT8634 targeting BRD9, CFT1946 targeting mutant BRAF, CFT8919 targeting mutant EGFR, and early-stage RET degrader programs. Founded in 2015, C4 Therapeutics collaborates with partners including F. Hoffmann-La Roche Ltd, Biogen MA, Inc., and Calico Life Sciences LLC.
Growth and profitability
Between FY2020 and FY2025, revenue grew at a 5-year CAGR of 1.6%. After falling to $20.8M in FY2023, revenue rose 71.4% to $35.6M in FY2024 and reached $35.9M in FY2025. Gross margin stood at 77.8% in FY2025, while operating margin remained negative at -290.7%, driven by $104.2M in R&D expense. Net income for FY2025 was -$105.0M, or -$1.22 per share. Over the trailing twelve months, revenue was $35.0M with an operating margin of -397.9% and an EPS of -$0.91. In the latest quarter ended June 30, 2026, quarterly revenue grew 2.8% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, C4 Therapeutics reported $253.7M in cash and short-term investments against total debt of $56.9M, providing net cash of $196.8M. The company maintains a current ratio of 5.45 and a debt-to-equity ratio of 0.23 across $247.3M in shareholders' equity. In FY2025, operating cash flow was -$98.7M and free cash flow was -$99.3M. Capital expenditures totaled $607,000, while share buybacks were $193,000, following a 169.5% increase in share count over five years.
Valuation and performance
C4 Therapeutics has a market capitalization of $340.2M and an enterprise value of $182.1M. The stock trades at a price-to-sales multiple of 9.7x and an EV-to-revenue multiple of 5.2x, compared to a price-to-sales ratio of 4.1x for the median of its US-listed Healthcare peers. Its price-to-book ratio is 1.5x. Over the past year, the stock returned 11.5% compared to 16.8% for the S&P 500 (SPY), while its 5-year return of -93.7% trails the benchmark's 83.0% gain.
What analysts expect
Wall Street coverage consists of 6 Strong Buy ratings and 2 Buy ratings, with 0 Hold or Sell recommendations. The mean price target is $12.86, representing a 365.0% premium over the October 16, 2026 closing price of $2.77. The company beat EPS estimates in each of the last 4 quarters. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.86 on revenue of $26.4M. For next fiscal year, 5 analysts forecast revenue to fall 15.6% to $22.3M. The next earnings date is November 5, 2026.
Key risks and what to watch
- High ongoing research and development costs of $104.2M in FY2025 could quickly deplete the company's $253.7M cash reserve without future milestone payments or financing.
- Short interest represents 33.0% of the float, pointing to elevated skepticism and potential volatility alongside a beta of 3.08.
- The company remains deeply unprofitable with a trailing twelve-month profit margin of -289.4% and an EPS of -$0.91.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this CCCC AI stock analysis
This page is an AI-written research summary of C4 Therapeutics, Inc. (CCCC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: CCCC income statement, CCCC balance sheet, CCCC key metrics, CCCC analyst forecast, CCCC chart. See the CCCC stock overview for the latest quote and news.
CCCC AI stock analysis FAQ
What is C4 Therapeutics' core technology and pipeline focus?
C4 Therapeutics develops targeted protein degradation therapies, primarily MonoDAC and BiDAC degraders, targeting diseases such as multiple myeloma, non-Hodgkin lymphomas, and various solid tumors. Its lead Phase 1/2 clinical candidate is CFT7455, supported by other programs such as CFT8634, CFT1946, and CFT8919.
How much cash does C4 Therapeutics have to fund operations?
As of June 30, 2026, C4 Therapeutics held $253.7M in cash and short-term investments against $56.9M in total debt. This provides a net cash position of $196.8M and a current ratio of 5.45.
Does C4 Therapeutics pay a dividend?
No, C4 Therapeutics does not pay a dividend. The company directs its capital toward research and development, which totaled $104.2M in FY2025.
What are analysts forecasting for C4 Therapeutics' earnings and stock price?
Analysts maintain a mean price target of $12.86, which is 365.0% above its last close of $2.77. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.86 on revenue of $26.4M.